Oral Presentations 2- Immunosuppressive drugs

10:30 • 753 • Real-world tacrolimus exposure during the first year after liver transplantation using abbreviated sampling and Bayesian estimation > P. Patricio Más-Serrano 10:43 • 698 • Translational PBPK Model Development for Tacrolimus: Mechanistic Integration of Growth, Postoperative Changes, and Voriconazole Interaction > M. Ma Yi 10:56 • 723 • Mechanistic PBPK Modeling of Sirolimus Reveals the Importance of Red Blood Cell Partitioning > T. Takanobu Nadai 11:09 • 421 • TacDDI: A precision dosing tool integrating Bayesian estimation to manage complex drug-drug interactions > R. Racym BERRAH 11:22 • 224 • REtrospective analysis of the inFLuence of antibiotic treatments on the pharmacokinEtics of taCrolimus in kidney Transplant patients (REFLECT study) > A. Alice BARBÉ 11:35 • 302 • Development and External Evaluation of a Whole-Blood and Intracelluar Tacrolimus Population Pharmacokinetic Model in Liver and Kidney Transplant Recipients > S. Samuel Baroudi 11:48 • 580 • Study of tacrolimus exposure in kidney transplant patients: Contribution of AUC and C0/dose ratio > A. Amina NAMANI